American Heart Journal
Volume 148, Issue 5 , Pages 834-841 , November 2004

Effect of age on the use of evidence-based therapies for acute myocardial infarction

  • Chau T.T. Tran, PhD

      Affiliations

    • University of Toronto, Institute of Medical Sciences, Toronto, Ontario, Canada
    • Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada
    • ,
  • Andreas Laupacis, MD, MSc

      Affiliations

    • Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada
    • University of Toronto, Clinical Epidemiology and Health Care Research program (Sunnybrook and Women's College site) and Department of Medicine and Health Policy Management and Evaluation, Division of General Internal Medicine Medicine Sunnybrook and Women's College Health Sciences Centre, Toronto, Ontario, Canada
    • ,
  • Muhammad M. Mamdani, PharmD, MA, MPh

      Affiliations

    • Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada
    • University of Toronto, Faculty of Pharmacy, Toronto, Ontario, Canada
    • ,
  • Jack V. Tu, MD, PhD

      Affiliations

    • Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada
    • University of Toronto, Clinical Epidemiology and Health Care Research program (Sunnybrook and Women's College site) and Department of Medicine and Health Policy Management and Evaluation, Division of General Internal Medicine Medicine Sunnybrook and Women's College Health Sciences Centre, Toronto, Ontario, Canada
    • Corresponding Author InformationReprint requests: Jack V. Tu, MD, PhD, Institute for Clinical Evaluative Sciences, G106-2075 Bayview Ave, Toronto, Ontario, Canada M4N 3M5.

Received 6 June 2003 ,Accepted 6 April 2004.

References 

  1. Statistics Canada. Census 2001. 2002
  2. The changing face of heart disease and stroke in Canada. Ottawa: Heart and Stroke Foundation of Canada; 2000. p. 1–107
  3. Antiplatelet Trialists' Collaboration . Collaborative overview of randomised trials of antiplatelet therapy—I (prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients). BMJ. 1994;308:81–106
  4. Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI). Lancet 1986;1:397–402
  5. Randomised trial of intravenous atenolol among 16,027 cases of suspected acute myocardial infarction: ISIS-1. First International Study of Infarct Survival Collaborative Group. Lancet 1986;2:57–66
  6. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group [comments]. Lancet 1995;345:669–85
  7. Scandinavian Simvastatin Survival Study Group . Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease (the Scandinavian Simvastatin Survival Study). Lancet. 1994;344:1383–1389
  8. Marciniak TA, Ellerbeck EF, Radford MJ, et al.  Improving the quality of care for Medicare patients with acute myocardial infarction (results from the Cooperative Cardiovascular Project). JAMA. 1998;279:1351–1357
  9. Krumholz HM, Radford MJ, Wang Y, et al.  National use and effectiveness of beta-blockers for the treatment of elderly patients after acute myocardial infarction (National Cooperative Cardiovascular Project). JAMA. 1998;280:623–629
  10. Scott IA, Eyeson-Annan ML, Huxley SL, et al.  Optimising care of acute myocardial infarction (results of a regional quality improvement project). J Qual Clin Pract. 2000;20:12–19
  11. Alpert JS. Acute coronary syndromes observed from an international perspective. Eur Heart J. 2002;23:1139–1140
  12. Tu JV, Austin P, Naylor CD, et al.  Acute myocardial infarction outcomes in Ontario: methods appendix. In:  Naylor CD,  Slaughter P editor. Cardiovascular health and services in Ontario. Toronto: Institute for Clinical Evaluative Sciences; 1999;p. 25–30
  13. Anonymous . International Classification of Disease 9th Revision: Clinical modification; ICD-9 CM annotated. 9th Revision ed. Ann Arbor: Commission on Professional and Hospital Activities; 1991;
  14. Landis JR, Koch GG. An application of hierarchical kappa-type statistics in the assessment of majority agreement among multiple observers. Biometrics. 1977;33:363–374
  15. Tran CT, Lee DS, Flintoft VF, et al.  CCORT/CCS quality indicators for acute myocardial infarction care. Can J Cardiol. 2003;19:38–45
  16. Ryan TJ, Anderson JL, Antman EM, et al.  ACC/AHA guidelines for the management of patients with acute myocardial infarction (a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction)). J Am Coll Cardiol. 1996;28:1328–1428
  17. Fallen EL, Cairns J, Dafoe W, et al.  Management of the postmyocardial infarction patient (a consensus report–revision of 1991 CCS guidelines). Can J Cardiol. 1995;11:477–486 review
  18. Tu JV, Austin P, Rochon PA, et al.  Secondary prevention after acute myocardial infarction, congestive heart failure, and coronary artery bypass graft surgery in Ontario. In:  Naylor CD,  Slaughter P editor. Cardiovascular health and services in Ontario: an ICES Atlas. Toronto: ICES; 1999;p. 199–238
  19. Jansen RW, Gurwitz JH. Controversies surrounding the use of beta-blockers in older patients with cardiovascular disease. Drugs Aging. 1994;4:175–183
  20. Guidelines for lipid testing: guideline number CLP017. Toronto: Ontario Association Medical Laboratories; 1998. p. 1–5
  21. Grover SA, Coupal L, Fahkry R, et al.  Screening for hypercholesterolemia among Canadians (how much will it cost?). CMAJ. 1991;144:161–168
  22. Yarzebski J, Spencer F, Goldberg RJ, et al.  Temporal trends (1986–1997) in cholesterol level assessment and management practices in patients with acute myocardial infarction (a population-based perspective). Arch Intern Med. 2001;161:1521–1528
  23. Rogers WJ, Canto JG, Lambrew CT, et al.  Temporal trends in the treatment of over 1.5 million patients with myocardial infarction in the U.S. from 1990 through 1999. J Am Coll Cardiol. 2000;36:2056–2063
  24. McLaughlin TJ, Soumerai SB, Willison DJ, et al.  Adherence to national guidelines for drug treatment of suspected acute myocardial infarction (evidence for undertreatment in women and the elderly). Arch Intern Med. 1996;156:799–805
  25. Spencer F, Scleparis G, Goldberg RJ, et al.  Decade-long trends (1986 to 1997) in the medical treatment of patients with acute myocardial infarction (a community-wide perspective). Am Heart J. 2001;142:594–603
  26. Galcera-Tomas J, Castillo-Soria FJ, Villegas-Garcia MM, et al.  Effects of early use of atenolol or captopril on infarct size and ventricular volume (a double-blind comparison in patients with anterior acute myocardial infarction). Circulation. 2001;103:813–819
  27. Barron HV, Michaels AD, Maynard C, et al.  Use of angiotensin-converting enzyme inhibitors at discharge in patients with acute myocardial infarction in the United States (data from the National Registry of Myocardial Infarction 2). J Am Coll Cardiol. 1998;32:360–367
  28. Lee PY, Alexander KP, Hammill BG, et al.  Representation of elderly persons and women in published randomized trials of acute coronary syndromes. JAMA. 2001;286:708–713
  29. Ayanian JZ, Hauptman PJ, Guadagnoli E, et al.  Knowlege and practices of generalist and specialist physicians regarding drug therapy for acute myocardial infarction. N Engl J Med. 1994;331:1136–1142
  30. Salomaa V, Miettinen H, Niemela M, et al.  Relation of socioeconomic position to the case fatality, prognosis and treatment of myocardial infarction events; the FINMONICA MI register study. J Epidemiol Community Health. 2001;55:475–482
  31. O'Connor GT, Quinton HB, Traven ND, et al.  Geographic variation in the treatment of acute myocardial infarction (the Cooperative Cardiovascular Project). JAMA. 1999;281:627–633

☆ Supported by an operating grant from the Canadian Institutes for Health Research. Ms Tran is supported by a Canadian Institutes for Health Research Doctoral Fellowship and was a recipient of the Heart and Stroke Foundation Fellowship (Richard Lewar Centre of Excellence). Dr Tu is supported by a Canada Research Chair in Health Services Research. The Institute for Clinical Evaluative Sciences is supported in part by a grant from the Ontario Ministry of Health and Long-Term Care. The results, conclusions and opinions are those of the authors and no endorsement by the Ministry, the Institute, or the Canadian Institutes for Health Research is intended or should be inferred.

PII: S0002-8703(04)00291-1

doi: 10.1016/j.ahj.2003.11.028

American Heart Journal
Volume 148, Issue 5 , Pages 834-841 , November 2004

Article Tools

* Image Usage & Resolution